Sorry, you need to enable JavaScript to visit this website.
Skip to main content
REPORT

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand
KR -  Seoul (Gangnam)
KR -  Gyeonggi-do
KR -  Seoul City Airport

North America

US -  Boston

GLOBAL

English

CAREERS

SOLUTIONS

RESOURCES

ABOUT US

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
CN -  Taipei City
TH -  Bangkok
NZ -  New Zealand
KR -  Seoul (Gangnam)
KR -  Gyeonggi-do
KR -  Seoul City Airport

North America

US -  Boston

GLOBAL

English

Accelerating Genetic Therapy Clinical Trials in Asia-Pacific

A growing number of biotechnology companies, both in the West and in Asia, are specializing in gene therapies and other regenerative treatments boosted by the approval of the first genetic therapy agent (tisagenlecleusel) by the FDA in 2017. Between 2015 and 2019, the number of industry-sponsored genetic therapy trials more than quadrupled (CAGR + 43%), with the Asia-Pacific region being involved in about 40% of all trials (ex-Japan). Since 2001, over 300 sites in Asia-Pacific have been involved in 335 different genetic therapy trials. 

By downloading, you confirm that you agree to the storing and processing of your personal data as described in our Privacy Statement.